Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by BearDownAZon Nov 24, 2019 6:22pm

103 Views

Post# 30387692

RE:Not all LDL is the same

Thanks for sharing Barsax. Yes, I too think this may explain the efficacy of apabetalone in the below median LDL-C population. I brainstormed on this the other day over on Agoracom. ----------------------------------------------------------------------https://agoracom.com/ir/Resverlogix/forums/discussion/topics/733727-balancing-success-and-failure/messages/2249657#message

Bullboard Posts

Investor’s corner: Solving chronic pain in dogs – A significant market opportunity